

# GSK Q1 2017 results



## GSK Group

### Sales

£7.4bn

+19% AER | +5% CER

### Total EPS

21.4p

>100% AER  
>100% CER

### Adjusted EPS

25.0p

+31% AER | +9% CER

### Improved Group operating margin

### Free cash flow

£0.7bn

## Sales growth across all three businesses

### Pharmaceuticals

£4.2bn | 34.4%

+17% AER | +4% CER

Operating margin

Driven by growth of new products, partly offset by divestments

### Vaccines

£1.2bn | 29.6%

+31% AER | +16% CER

Operating margin

Continued momentum from meningitis and established vaccines

### Consumer Healthcare

£2.0bn | 17.2%

+16% AER | +2% CER

Operating margin

Strong performances in oral health and cold & flu partly offset by disposal, continuing weakness in some international markets and late start to allergy season

See [press release](http://www.gsk.com) on [www.gsk.com](http://www.gsk.com) for details on Q1 2017

Please read this cautionary statement regarding [forward-looking statements](#)